Secretome | Patients

Why Focus on DMD Associated Cardiomyopathy?

DMD: A Disease of Skeletal and Cardiac Muscle

01

Duchenne muscular dystrophy is a debilitating myopathy resulting in progressive functional decline & early death

02

Cardiomyopathy is the leading cause of death and is not addressed by currently available therapies

03

Cardiac fibrosis & loss of left ventricular ejection fraction (LVEF) correlate with heart failure and morality¹

1. Soslow et al. 2023 PMID: 37288563

Key Features of THRIVE 2

The THRIVE 2 Study is an Open-Label Study to Evaluate the Safety and Efficacy of STM-01 in Pediatric and Adult Participants with Duchenne Muscular Dystrophy-Cardiomyopathy

Home Dosing

Treatment administered in the comfort of the home environment

No Wash-Out Period

Patients continue current standard of care without interruption

No Age Maximum

Open to eligible pediatric and adult participants with DMD-cardiomyopathy

No Ambulation Limits

Open to ambulatory, late-ambulatory, and non-ambulatory participants

No Medication Limits

Participants are eligible regardless of previous or current medication

Step 1

Screening

Eligibility assessment &
informed consent

Step 2

Enrollment

Eligibility assessment &
informed consent

Step 3

Treatment & Home Dosing

STM-01 administration with
no wash- out period

Step 4

Follow-Up

Safety & efficacy monitoring
including LVEF

Resources for Families

We stand with the broader DMD community and partner organizations supporting patients and their families.

Questions?

Email: advocacy@secretometx.com

Dedicated to Patients with Orphan & Underserved Chronic Diseases